On February 19th, Altria Group announced on its official website that its CEO Billy Gifford and CFO Sal Mancuso will attend the Consumer Analyst Group of New York (CAGNY) conference, where they will reaffirm the company's full-year profit expectations for 2025.
Gifford emphasized in his speech that Altria is driving strategic transformation through its "Optimize & Accelerate" plan, with the goal of leading adult smokers towards a smoke-free future.
Our long-term competitiveness in the U.S. nicotine market stems from our commitment to responsibility, deep understanding of consumer demands, and a diverse portfolio covering all non-smoking product categories. Strong cash flow and a flexible balance sheet will support investments and shareholder returns.
Altria listed multiple potential risks in its announcement, including:
- Regulatory Uncertainty: FDA may implement a ban on mint-flavored cigarettes (expected to impact company revenue by 15%);
- Illegal e-cigarette Impact: By 2024, the illegal e-cigarette market share may reach 40%, squeezing space for compliant brands like NJOY;
- Supply Chain Pressure: Drought in Brazil, the main tobacco producing region, has led to an approximate 8% increase in procurement costs.
In the traditional tobacco business sector, Philip Morris International (PMI) reported a 4.5% decrease in cigarette shipments in 2024, but achieved a 1.2% revenue growth through pricing strategies. In the new tobacco product sector, NJOY e-cigarette is the only pod system certified by the FDA's PMTA, with a 32% year-on-year increase in sales in 2024, but limited by pricing constraints with a gross margin of only 45%. The nicotine pouch brand "On!" holds a market share of 28%, and Altria plans to launch a new product without tobacco ingredients in 2025. A joint venture project with Japan Tobacco (JT) is expected to release its first product in Q4 of 2025.
Gifford emphasized that Altria is facing three-way pressure from British American Tobacco, Juul, and Chinese brands. Its subsidiary brand NJOY differentiates itself with a focus on FDA compliance, making it one of the few e-cigarette brands in the US market to be certified through the PMTA process. Philip Morris International's IQOS holds a 70% global market share, and Altria will need to break through technological barriers through the Horizon joint venture project. At the same time, regulatory environment is tightening, with the FDA planning to introduce new nicotine product standards in the second quarter of 2025, potentially limiting the use of synthetic nicotine. This will pose a challenge for Altria.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
